Background {#Sec1}
==========

Polycystic ovary syndrome (PCOS) is the commonest endocrinopathy in women andthe commonest cause of anovulatory infertility. The aetiology is largely unknown. It has a high degree of heritability but the search for confirmed candidate genes has proved elusive. The developmental hypothesis for the origin of PCOS, based on the Barker hypothesis \[[@CR1]\], suggests that exposure of the fetus to excess androgens influences imprinting, leading to altered genetic expression in adult life. This re-programming of the female reproductive axis is thought to induce the features of PCOS in later life: oligo/anovulation, polycystic ovaries, hyperandrogenism and insulin resistance. Additionally, the woman with PCOS has a more than two-fold risk of developing the metabolic syndrome, type-2 diabetes and cardiovascular disease. The extent of the human suffering and economicburden of PCOS must encourage research into its origins which would surely reveal the possibility of innovative treatments and possible preventative measures for this very prevalent condition.

Studies on pregnant monkeys injected with testosterone \[[@CR2]\], prevalenceof tom-boy behaviour of female children \[[@CR3]\] and even an increased incidence of autism spectrum disorders \[[@CR4]\], have all corroborated the possible influence of hyper-exposure to testosterone in-utero. Prenatal exposure of experimental animals to androgens produces endocrine and metabolic alterations in offspring resembling those in PCOS \[[@CR5]--[@CR8]\]. These latest studies clearly suggest thatfetal over-exposure to androgens could be the main factor in PCOS pathogenesis.

The first step in proving the developmental hypothesis for the origin of PCOS is evidence that the susceptible fetus may indeed be exposed to a hyperandrogenic environment. Androgens influence the production of sebum by exerting an effect on sebaceous gland activity \[[@CR9]\]. At the 18th week of fetal life, the sebaceous glands are fully differentiated and at birth they are fully functional. If the fetus is exposed to maternal androgens in utero, neonatal seborrhoea should provide a surrogate measure of the extent of in-utero exposure of the fetus to androgensas this would translate to increased sebaceous gland activity in the neonate.

The aim of this pilot study was to examine whether the female fetus of a mother with PCOS is indeed exposed to excess androgens.

Methods {#Sec2}
=======

This is a prospective case control study to discern whether neonatal sebum excretion is greater in female infants born to PCOS mothers compared to non-PCOS.Followinglocal ethical committee permission (Central London, 13/LO/0510)and signing of informed consent, women with known PCOS (all three Rotterdam criteria \[[@CR10]\])(*n* = 9) and non-PCOS controls (*n* = 12), with a female fetus, were recruited at 24 weeks pregnancy and serum testosterone estimated. They were next seen in labour at a single University Hospital.

The absorbent paper technique (Sebutape®),is a rectangular white adhesive tape containing micro-cavities to trap sebum. The surface is hydrophobic. As the sebum issues from the follicles it is trapped in the cavities and the tape becomes transparent. Sebum excretion can therefore be assessed and the number of active secreting sebaceous follicles over an 8x8mm area captured. The skin is pre-cleaned with an alcohol wipe to remove causal sebum and the contact time, pressure, temperature and humidity are standardised to give reliable, reproducible results (Fig. [1](#Fig1){ref-type="fig"}). Once the process is completed the sebutapes are placed onto a black card where the transparent areas are seen as black dots.Fig. 1The absorbent paper technique of measuring sebum excretion rates (Sebutape®), on a semi-quantitative scale from 1 (no sebum) to 5 (serious seborrhoea)

Sebum excretion was measured for 30 min and 60 min to ensure slow secreting follicles were captured. This was done within 24 h of birth, at 1 week, 4--6 weeks and 6 months after birth in both mother and child. Sebum excretion was measured at the same site at each time frame as the amount of sebum per unit skin surface is generally constant in an individal and on a given anatomical site. This was done consistently for mother and baby.

All semi-quantitative sebum excretion estimations were compared (t-test) between the two groups and correlated with testosterone concentrations during pregnancy.

Results {#Sec3}
=======

As would be expected, women with PCOS had a significantly higher mean BMI and a higher mean serum total testosterone concentration at 24 weeks gestation compared with controls but the groups were otherwise demographically similar (Table [1](#Tab1){ref-type="table"}). Six of the 9 in the PCOS group compared with 2 of the 12 controls had a serum testosterone \>3.12 pmol/L.Table 1Details of PCOS mothers and controlsPCOS (*n* = 9)Controls (*n* = 12)*P* valueMean age (SD)30.1 (4.76)31.6 (3.5)0.42Mean BMI (SD)31.1 (4.7)25.2 (4.1)0.007Mean T (nmol/l)(SD)6.2 (5.6)2.75 (1.4)0.11*BMI* body mass index, *T* total serum testosterone, *SD* standard deviation, *NS* not significant

Results of sebum excretion measured at 30 min and 60 min were almost identical.

Maternal sebum production was reasonably stable throughout from 24 weeks pregnancy to 6 months post natal. Any detectable neonatal sebum within 24 h of delivery was no longer evident 4 weeks later.

Serum testosterone in mothers with sebum positive newborn was 7.03 +/− 6.3 pmol/l compared with 2.77 +/− 1.4 in the remainder (*P* = 0.04)(Table [2](#Tab2){ref-type="table"}). Neonatal sebum excretion, which couldindicate in-utero exposure to excess androgens, was evident in 6 of 9 infants born to mothers with PCOS compared to 1of 12 mothers without PCOS (*P* = 0.005). There was no difference in the gestational age at birth between the sebum positive and sebum negative newborn (38.4 vs 38.8 weeks respectively) nor in the mode of delivery although sebum positive newborn had a significantly higher birth weight (Table [2](#Tab2){ref-type="table"}).Table 2Comparison of sebum positive and sebum negative groups within 24 h of birthSebum positive (*n* = 7)Sebum negative (*n* = 14)*P*PCOS group63Controls1110.005Mean birth weight (kg)(SD)3.58 (0.44)3.1 (0.410.02Mean gestational age (weeks)38.438.8NSMode of delivery Spontaneous36 Vacuum extraction02 Caesarean section46NSMothersMean T (nmol/l)(SD)7.03 (6.3)2.77 (1.4)0.04BMI (SD)31.7 (4.84)25.7 (4.19)0.02*BMI* body mass index, *T* serum testosterone, *SD* standard deviation, *NS* not significant

Discussion {#Sec4}
==========

Although animal studies laid the foundations of the developmental hypothesis for PCOS etiology, in humans this theory was doubtedfor many years. Although maternal testosterone concentrations are significantly higher in both serum and amniotic fluid compared to normal controls \[[@CR11]--[@CR13]\],the human fetus is protected from the effects of excessive maternal androgens by a combination of high concentrations of plasma binding proteins and a high level of placental aromatase activity. In human pregnancy, androgens are metabolized to estrogens by placental P450 aromatase \[[@CR14]\].

The hormonal alterations during pregnancy in PCOS women show that the uterine environment in PCOS is most probably hyper-androgenic.The results of initial autopsies of placentae from women with PCOS, showing macroscopic and microscopic alterations compared to healthy controls \[[@CR15]\] were also confirmed with altered histopathological findings in PCOS placentae in recent studies \[[@CR8]\].

When placental tissues from women with PCOS and healthy women were compared, changes in the activities of important enzymes for steroid synthesis were noticed. Specifically higher 3β-HSD-1 activity and lower P450 aromatase activity were seen in placenta tissue of women with PCOS. These alterations could increase androgen production during pregnancy according to the authors, as these enzymes are principally linked to placental steroidogenesis \[[@CR8]\]. It seems that placental altered steroidogenesis could play a key role in PCOS pathogenesis.

This pilot study has shown that a simple method for detecting fetal exposure to excess androgens is feasible. Clearly 30 min measuring was sufficient and the fact that sebum excretion was unmeasurable in the newborn one month after birth strongly suggests that the origin of the androgen hyper-exposure in PCOS is maternal and not fetal and that any effect of this androgen exposure originates during pregnancy rather than afterwards. Previous studies employing different methods of measuring sebum excretion, one very small \[[@CR16]\] and one that also included males and had no mention of PCOS \[[@CR17]\] found high perinatal sebum excretion in both sexes.

Following the results of this pilot study we are now proceeding with the use of more robust methods for sebum excretion measurement in order to confirm our original findings suggesting that women with PCOS hyper-expose their fetus to androgens.

Conclusions {#Sec5}
===========

The higher sebum production in babies of PCOS mothers strongly suggests hyper-exposure of the fetus in-utero to androgens. Confirmation is required but in line with the developmental theory of PCOS, this simple novel method could potentially be used within 24 h of birth to predict development of PCOS in adult life and induce research to eliminate the symptoms of PCOS.
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